Mosaic ImmunoEngineering secures exclusive worldwide CPMV license from Case Western Reserve University

Mosaic ImmunoEngineering Inc.

Licensed technology covers cowpea mosaic virus (CPMV)-based oncology treatments for human and companion animal cancers.
Development milestone payments up to $1.8M per human product; tiered royalties starting in mid-single digits on net sales.
Annual minimum royalty of $10,000 starting year 2, rising based on net sales; CWRU to be reimbursed ~$278K in IP fees.
Agreement term runs 20 years or last patent expiry; Mosaic gains rights to core technology behind lead candidate MIE-101.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.